Navigation Links
An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists
Date:3/10/2010

WALTHAM, Mass., March 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an acute migraine therapy that is not contraindicated in patients with a history, symptoms or signs of vascular disease and also offers improved efficacy and fast-acting oral delivery would earn a 45 percent patient share in the treatment of migraine, according to surveyed U.S. neurologists. In Europe, such an agent would earn a 30 percent patient share, according to surveyed European neurologists.

The new report entitled Migraine (Acute): Neurologists' Expectations for a New Acute Therapy Extend Beyond Cardiovascular Safety finds that a new acute migraine drug that is free of the triptans' risk of cardiovascular side effects would be valued by clinicians and would enjoy a unique competitive advantage. However, the report shows that such an advantage would not be sufficient to fulfill surveyed neurologists' expectations for a new acute treatment.  

The report also finds Zogenix/Astellas Pharma/Desitin Pharmaceuticals' Sumavel DosePro (needle-free subcutaneous injectable sumatriptan) will earn Decision Resources' proprietary gold-standard status for migraine in 2013. Sumavel DosePro was launched in the U.S. in January 2010 and has been filed for approval in Europe. In 2009, Decision Resources' gold standard for migraine was Merck's Maxalt (rizatriptan oral tablet), owing in part to modest advantages in efficacy over other oral triptans. According to the report, Sumavel DosePro has competitive advantages in efficacy as compared to Maxalt on several of the end points that are most important to surveyed neurologists.  

"Among the current and emerging therapies profiled in the report, Sumavel DosePro benefits from fast-acting and robust efficacy at early time points," said Decision Resources Analyst Jon Searles. "Despite disadvantages in sustained pain freedom and certain side effects, Sumavel DosePro will become our clinical gold standard for migraine in 2013, although we forecast its use will be limited owing to its high cost, generics competition, reimbursement challenges and patient preference for oral pills."

About the Report

Migraine (Acute): Neurologists' Expectations for a New Acute Therapy Extend Beyond Cardiovascular Safety is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development. 

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

For more information, contact:

Decision Resources

Christopher Comfort

781-296-2597

ccomfort@dresources.com

SOURCE Decision Resources

Back to top

RELATED LINKS
http://www.decisionresources.com

'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
2. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
5. Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
6. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
7. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
8. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
9. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
10. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
11. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... LITTLE FALLS, N.J., Dec. 8, 2016 CANTEL MEDICAL ... net income of $18,800,000, or $0.45 per diluted share, on ... the first quarter ended October 31, 2016. This compares with ... sales of $153,779,000 for the first quarter ended October 31, ... the first quarter ended October 31, 2016 to $21,323,000, or ...
(Date:12/8/2016)... 8, 2016 Research and Markets has announced the ... report to their offering. ... The report provides separate comprehensive analytics ... , and Rest of World. Annual estimates and forecasts ... analysis is provided for these markets. Market data and analytics are derived ...
(Date:12/7/2016)... 7, 2016 KEY FINDINGS ... such as reducing loss of blood during surgeries, ... arrests, rapid recovery after surgeries, and decreasing risks ... segmented into convective warming system, surface warming systems, ... reduce the stay at hospitals thus, lowering the ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare is in ... Botelho advocates for the mass media launching of story movements to highlight what's ... share their unfortunate experiences; such a movement can generate the network power to ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dianne Michael ... headquartered in Hamilton County, is embarking on a charity drive with the aim ... new homes for orphaned or neglected senior dogs in the Cincinnati region, and ...
(Date:12/8/2016)... ... , ... Coppin Insurance Agency, an insurance and financial planning firm based in ... area, is embarking on a charity drive with the goal of providing support and ... Food Bank of Southwest Florida works to provide fresh and nutritious food free of ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... to families and business owners in and around central Kansas, is joining the ... at-risk youth in the region. , Headquartered in Wichita, Youth Horizons works to ...
(Date:12/7/2016)... Alexandria, VA (PRWEB) , ... December 07, 2016 ... ... nation are celebrating the passage of the most comprehensive mental health systems reform ... Congress, the support of the President, and the commitment of our elected officials ...
Breaking Medicine News(10 mins):